Skip to main content
Premium Trial:

Request an Annual Quote

Bernard Tobin

Myriad Genetics has appointed Bernard Tobin as president of Crescendo Bioscience. Tobin joins Myriad from Amgen, where over the past seven years he has held various leadership roles, including executive director of national accounts, general manager of theNetherlandsandBrazil, as well as global head of commercial excellence. Before Amgen, Tobin had worked at Eli Lilly and Co.

Tobin will take over for William Hagstrom and report to Myriad CEO Peter Meldrum. Hagstrom has decided to leave Crescendo to pursue startup and social venture opportunities. He will stay with the company until Jan. 2, 2015, and Tobin's appointment will be effective as of Jan. 5.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more